Teijin & BioVaram Form Alliance to Boost Regenerative Medicine and Medical Devices in Japan & India

Teijin and BioVaram Form Strategic Alliance to Expand Regenerative Medicine and Implantable Medical Devices Across Japan and India

Hyderabad, 14th November, 2025: Hyderabad-based biotechnology company BioVaram, the brand of UR Advanced Therapeutics Pvt. Ltd. (URAT), and Japan’s Teijin Limited today announced a strategic business alliance to expand the use of Teijin Group’s implantable medical devices and regenerative medicine products in India, while introducing BioVaram’s advanced biotechnology portfolio into the Japanese market.

The collaboration stems from a shared vision to address unmet medical needs in Japan—one of the world’s most advanced healthcare ecosystems and India, where rapid innovation is reshaping the life sciences sector. The alliance will leverage the complementary strengths of both organizations to deliver next-generation therapeutic solutions across both geographies.

Under the agreement, Teijin and BioVaram will jointly explore:

• Regulatory approval and commercialization of SYNFOLIUMⓇ, a cardiovascular repair patch developed by Teijin Medical Technologies Co., Ltd., for the Indian market.

• Expansion opportunities for regenerative medicine products developed by Japan Tissue Engineering Co., Ltd. (J-TEC), a Teijin Group company, in India.

• Development and commercialization in Japan of BioVaram’s technologies, including exosome-based diagnostics and therapeutics, extracellular matrix mimics, and bio-derived materials such as Type I atelocollagen.

Takayuki Nakano, Ph.D., Mission Executive and General Manager of the Regenerative Medicine & Implantable Medical Device Division at Teijin Limited, stated:

“Partnering with UR Advanced Therapeutics is a significant milestone in Teijin’s global expansion in regenerative medicine and implantable medical devices. By combining our technological expertise with BioVaram’s innovative capabilities and market presence in India, we are confident in delivering advanced therapies that meet critical unmet needs in both countries.”

Jaganmohan Reddy, Founder and CEO of UR Advanced Therapeutics, added:

“This MoU marks the beginning of bringing India’s next-generation biotech innovations to the global stage. It strengthens BioVaram’s vision to build transformative biotech solutions through international collaboration. The partnership enhances our research and manufacturing capabilities in advanced tissue engineering while enabling Teijin to introduce BioVaram’s products to global markets. Together, we are shaping a future where biotechnology is impactful, accessible, and humane.”

Teijin established its Regenerative Medicine and Implantable Medical Devices division in 2022 by integrating Teijin Medical Technologies (bioabsorbable implantable devices), J-TEC (a pioneer in regenerative medicine), and Teijin Regenet Co., Ltd. (a dedicated CDMO for regenerative therapies). The division continues to grow with a mission to restore lost tissues and functions for patients worldwide.

BioVaram, headquartered in Hyderabad, is a rapidly emerging biotechnology company known for its innovative regenerative medicine solutions. Its portfolio includes AI-designed peptides, exosome-based therapeutics and diagnostics, and advanced bio-derived materials. The company has earned multiple recognitions, including being named a “Top 5 Startup” at BioAsia 2024.

Looking ahead, Teijin and BioVaram will evaluate business feasibility, regulatory pathways, technical integrations, and market requirements to advance these initiatives. They will also collaborate on product development and manufacturing in cell and gene therapy, while progressing plans to introduce SYNFOLIUMⓇ in India.